AL-3778 (also known as ALS-003778;
JNJ-63595948; NVR-1221; NVR-3-778) is an experimental drug being developed by
Alios BioPharma, Inc. to treat Hepatitis B virus (HBV) infection . Hepatitis B is an
infectious disease caused by the hepatitis B virus which affects the
liver. It can cause both acute and chronic infections. The virus is transmitted
by exposure to infectious blood or body fluids. Infection around the time of
birth or from contact with other people's blood during childhood is the most
frequent method by which hepatitis B is acquired in areas where the disease is
common. In areas where the disease is rare, intravenous drug use and sexual
intercourse are the most frequent routes of infection.
 |
| A New Drug for the Treatment for Hepatitis B Virus (HBV) |
AL-3778
is currently in pre-clinical studies. It is also in Phase I trials in
combination with Entecavir or Tenofovir Disoproxil Fumarate in healthy volunteers
[1].
References:
1. ClinicalTrials.gov Study of the
Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With
Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers. NCT03032536
